Synergen's SLPI
Executive Summary
Company's natural elastase inhibitor designated an orphan product by FDA. The enzyme is being developed as a treatment for cystic fibrosis and genetic emphysema. Phase II trials are expected to begin later this year .... Antril: Synergen begins Phase II studies of the recombinant interleukin-1 receptor agonist in patients with sepsis and septic shock. The Boulder, Colorado- based biotech firm hopes to enroll 100 patients over the next six months.